Torrent Pharmaceuticals share news, announcements and annual reports
NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap
Torrent Pharmaceuticals Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Nov 2002 on NSE
Last close ₹4,557.00down ₹68.00 (1.47%)BSE ₹4,560.35
Share price at the NSE close on 28 Oct 2026. Previous close ₹4,625.00.
28 Oct: open ₹4,597.10, high ₹4,597.10, low ₹4,486.60
52-week range of traded prices to 28 Oct 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,73,334 Cr61st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 81.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.43
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.83%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.76
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,26,21557.8% delivered
Torrent Pharmaceuticals has 864 announcements on record, routine notices left out; 8 in the 30 days to 29 Oct 2026, the latest on 23 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Torrent Pharmaceuticals quarterly results
Oct23Fri
The board met on 23 Oct 2026 to consider other business matters and financial results
Notice filed 6 Oct 2026
Torrent Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Torrent Pharmaceuticals financials, year by year
Annual reports17
- Annual report, year to Mar 20261 Jun 2026
- Annual report, year to Mar 20254 Jul 2025
- Annual report, year to Mar 202429 Jun 2024
- Annual report, year to Mar 202314 Jul 2023, a zip file
- Annual report, year to Mar 20224 Jul 2022, a zip file
12 earlier reports
- Annual report, year to Mar 20212 Jul 2021, a zip file
- Annual report, year to Mar 20204 Jul 2020, a zip file
- Annual report, year to Mar 201924 Jun 2019, a zip file
- Annual report, year to Mar 20188 Aug 2018, a zip file
- Annual report, year to Mar 201710 Aug 2017, a zip file
- Annual report, year to Mar 201622 Aug 2016, a zip file
- Annual report, year to Mar 201516 Jul 2015, a zip file
- Annual report, year to Mar 20144 Jul 2014, a zip file
- Annual report, year to Mar 20135 Sep 2013, a zip file
- Annual report, year to Mar 201229 Jun 2012, a zip file
- Annual report, year to Mar 201120 Jun 2012, a zip file
- Annual report, year to Mar 201018 Aug 2010, a zip file
Investor presentations42
- Investor Presentation22 May 2026
- Investor Presentation13 Feb 2026
- Investor Presentation7 Nov 2025
- Investor Presentation28 Jul 2025
- Investor Presentation30 Jun 2025
37 earlier presentations
- Investor Presentation20 May 2025
- Investor Presentation24 Jan 2025
- Investor Presentation25 Oct 2024
- Investor Presentation23 Jul 2024
- Investor Presentation24 May 2024
- Investor Presentation2 Feb 2024
- Investor Presentation23 Oct 2023
- Investor Presentation7 Aug 2023
- Investor Presentation30 May 2023
- Investor Presentation25 Jan 2023
- Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 202221 Oct 2022
- Investor Presentation27 Sep 2022
- Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30th June, 202229 Jul 2022
- Presentation on Audited Financial Results for the quarter and year ended 31st March, 2022 to be made to analysts is enclosed for your records.25 May 2022
- Investor Presentation25 Jan 2022
- Investor Presentation26 Oct 2021
- Investor Presentation27 Jul 2021
- Investor Presentation18 May 2021
- Investor Presentation to analysts on unaudited Consolidated Financial Results for the quarterand nine months ended 31st December, 20208 Feb 2021
- Investor Presentation26 Oct 2020
- Investor Presentation30 Jul 2020
- Investor Presentation26 May 2020
- Investor Presentation27 Jan 2020
- Investor Presentation23 Oct 2019
- Investor Presentation23 Jul 2019
- Investor Presentation20 May 2019
- Investor Presentation30 Jan 2019
- Investor Presentation3 Nov 2018
- Investor Presentation2 Aug 2018, a zip file
- Investor Presentation30 May 2018, a zip file
- Investor Presentation11 Feb 2018, a zip file
- Investor Presentation8 Feb 2018, a zip file
- Investor Presentation3 Nov 2017, a zip file
- Investor Presentation26 May 2017, a zip file
- Investor Presentation3 Feb 2017, a zip file
- Presentation to analysts on un-audited Financial Results for the quarter and half year ended September 30, 201626 Oct 2016, a zip file
- Presentation to Analysts on Financial Results for quarter ended June 30, 2016.27 Jul 2016, a zip file
Earnings calls37
- Link of Recording23 Oct 2026
- Transcript4 Aug 2026
- Link of Recording30 Jul 2026
- Transcript27 May 2026
- Link of Recording22 May 2026
32 earlier call documents
- Transcript20 Feb 2026
- Link of Recording13 Feb 2026
- Transcript13 Nov 2025
- Link of Recording7 Nov 2025
- Transcript31 Jul 2025
- Link of Recording28 Jul 2025
- Transcript23 May 2025
- Link of Recording20 May 2025
- Transcript31 Jan 2025
- Link of Recording24 Jan 2025
- Transcript30 Oct 2024
- Link of Recording25 Oct 2024
- Transcript29 Jul 2024
- Link of Recording23 Jul 2024
- Transcript30 May 2024
- Link of Recording24 May 2024
- Transcript7 Feb 2024
- Link of Recording2 Feb 2024
- Transcript26 Oct 2023
- Link of Recording23 Oct 2023
- Link of Recording7 Aug 2023
- Transcript3 Jun 2023
- Link of Recording30 May 2023
- Transcript1 Feb 2023
- Link of Recording25 Jan 2023
- Transcript of Conference call with Analysts / Investors on Financial Results for the quarter and half year ended 30th September, 202228 Oct 2022
- Audio Recording of Conference call with Analysts / Investors on Financial Results for the quarter and half year ended 30th September, 202221 Oct 2022
- Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 20225 Aug 2022
- Audio Recording of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 202230 Jul 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call on Audited Financial Results of the Company for quarter and year ended 31st March, 202230 May 2022
- Recording of Analysts/Institutional Investor Meet/Con. CallIn continuation of our letter dated 20-May-22 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2022, has been placed on the Company's website at https://torrentpharma.com/pdf/investors/Audio_Recording31032022.mp325 May 2022
- Recording of Analysts/Institutional Investor Meet/Con. CallIn continuation of our letter dated 20-May-22 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2022, has been placed on the Company's website at https://www.torrentphanna.com/pdf/investors/ Audio Recording31032022.mp325 May 2022
Torrent Pharmaceuticals merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings3
- Scheme of Arrangement We would like to inform that Hon'ble National Company Law Tribunal, Ahmedabad Bench ("NCLT"), vide its Order dated 17th May, 2023, has sanctioned the Scheme of Arrangement in the nature of Amalgamation between Curatio Health Care (I) Private Limited, a wholly owned subsidiary of the Company with Torrent Pharmaceuticals Limited and their respective shareholders and creditors ("Scheme") pursuant to the provisions of Section 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules made thereunder. A copy of the said Order is available on the website of the Company.The above is in continuation to our earlier communication dated 21-Dec-22 intimating the approval of the said Scheme of Amalgamation by the Board of Directors of the Company in its meeting held on 21-Dec-22. The Scheme will become effective upon filing of the said Order with the Registrar of Companies, Gujarat. Kindly take note of the above.18 May 2023
- Amalgamation/MergerIntimation for approval of scheme of amalgamation of Curatio Health Care (I) Private Limited with Company21 Dec 2022
- Torrent Pharmaceuticals Limited has informed vide letter dated February 15, 2016 that " the Hon'ble High Court of Gujarat vide its Order dated 11-February-2016, sanctioned the Scheme of Amalgamation of Zyg Pharma Private Limited, a wholly owned subsidiary of the Company, with Torrent Pharmaceuticals Limited and their respective shareholders and creditors. The above is in continuation to our earlier communication dated 08-0ctober-2015 intimating the approval of the said Scheme of Amalgamation by the Board of Directors of the Company in its meeting held on 08-0ctober-2015".15 Feb 2016, a zip file
Torrent Pharmaceuticals share news and announcements
Newest first. Page 1 of 18.
Oct 2026
23 Oct · Results
16 Oct · Management
9 Oct · Analysts
7 Oct · Rating
6 Oct · Board meeting
Sep 2026
10 Sep · Analysts
7 Sep · Meeting
Aug 2026
11 Aug · Analysts
11 Aug
5 Aug · Meeting
1 Aug · Management
Jul 2026
30 Jul · Management
30 Jul · Results
27 Jul
17 Jul
17 Jul
17 Jul · Analysts
16 Jul · Board meeting
8 Jul
7 Jul · Corporate action
7 Jul
6 Jul
Jun 2026
23 Jun · Meeting
1 Jun · Updates
May 2026
30 May · Analysts
22 May · Corporate action
16 May · Analysts
12 May · Analysts
12 May · Analysts
Apr 2026
10 Apr
Mar 2026
30 Mar
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 26 Oct 2026Resultsup 0.57%−0.3 pts vs Nifty 500market median −0.7% · volume 2.1× usual · delivery −14.5 pts against usual · The announcement
- 19 Oct 2026Board or managers changeddown 0.00%+1.0 pts vs Nifty 500market median 0.0% · five sessions −0.2% (+2.8 pts vs Nifty 500) · volume 0.8× usual · delivery −3.4 pts against usual · The announcement
- 8 Oct 2026Credit ratingdown 2.10%−0.1 pts vs Nifty 500market median 0.0% · five sessions −2.9% (−2.8 pts vs Nifty 500) · volume 0.7× usual · delivery −9.6 pts against usual · The announcement
- 31 Jul 2026Resultsup 5.15%+4.7 pts vs Nifty 500market median −0.7% · five sessions +1.7% (+0.1 pts vs Nifty 500) · volume 1.7× usual · delivery −6.7 pts against usual · The announcement
- 31 Jul 2026Board or managers changedup 5.15%+4.7 pts vs Nifty 500market median 0.0% · five sessions +1.7% (+0.1 pts vs Nifty 500) · volume 1.7× usual · delivery −6.7 pts against usual · The announcement
- 25 May 2026Dividendup 1.93%+0.7 pts vs Nifty 500market median 0.0% · five sessions −3.0% (−2.1 pts vs Nifty 500) · volume 3.6× usual · delivery −23.3 pts against usual · The announcement
- 16 Feb 2026Dividendup 4.50%+3.8 pts vs Nifty 500market median 0.0% · five sessions +4.0% (+3.7 pts vs Nifty 500) · volume 5.4× usual · delivery −35.4 pts against usual · The announcement
- 6 Jan 2026Credit ratingup 1.73%+1.9 pts vs Nifty 500market median 0.0% · five sessions +2.1% (+4.3 pts vs Nifty 500) · volume 1.3× usual · delivery −15.4 pts against usual · The announcement
- 5 Jan 2026Credit ratingdown 0.40%−0.2 pts vs Nifty 500market median 0.0% · five sessions +2.0% (+4.6 pts vs Nifty 500) · volume 0.6× usual · delivery −2.1 pts against usual · The announcement
- 10 Nov 2025Resultsup 6.63%+6.3 pts vs Nifty 500market median −0.7% · five sessions +7.0% (+5.7 pts vs Nifty 500) · volume 10.3× usual · delivery −38.0 pts against usual · The announcement
20 earlier announcements
- 8 Oct 2025Credit ratingup 0.91%+1.3 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−0.3 pts vs Nifty 500) · volume 1.0× usual · delivery +0.7 pts against usual · The announcement
- 7 Oct 2025Credit ratingup 0.31%+0.1 pts vs Nifty 500market median 0.0% · five sessions −0.2% (−0.8 pts vs Nifty 500) · volume 1.6× usual · delivery +6.9 pts against usual · The announcement
- 29 Jul 2025Resultsup 4.01%+3.3 pts vs Nifty 500market median −0.7% · five sessions −0.3% (−0.3 pts vs Nifty 500) · volume 3.1× usual · delivery −31.1 pts against usual · The announcement
- 29 Jul 2025Board or managers changedup 4.01%+3.3 pts vs Nifty 500market median 0.0% · five sessions −0.3% (−0.3 pts vs Nifty 500) · volume 3.1× usual · delivery −31.1 pts against usual · The announcement
- 21 May 2025Resultsup 1.47%+0.8 pts vs Nifty 500market median −0.7% · five sessions −2.0% (−3.1 pts vs Nifty 500) · volume 3.4× usual · delivery −35.2 pts against usual · The announcement
- 20 Mar 2025Credit ratingup 1.24%+0.3 pts vs Nifty 500market median 0.0% · five sessions +0.9% (−1.1 pts vs Nifty 500) · volume 0.5× usual · delivery −6.8 pts against usual · The announcement
- 28 Feb 2025Board or managers changeddown 1.30%+0.8 pts vs Nifty 500market median 0.0% · five sessions +2.4% (+1.8 pts vs Nifty 500) · volume 6.4× usual · delivery −1.0 pts against usual · The announcement
- 27 Jan 2025Dividendup 2.75%+4.7 pts vs Nifty 500market median 0.0% · five sessions +0.6% (−0.6 pts vs Nifty 500) · volume 6.0× usual · delivery −11.7 pts against usual · The announcement
- 28 Oct 2024Resultsdown 3.38%−4.1 pts vs Nifty 500market median −0.7% · five sessions −6.6% (−8.1 pts vs Nifty 500) · volume 2.6× usual · delivery +13.8 pts against usual · The announcement
- 25 Oct 2024Credit ratingup 3.36%+4.6 pts vs Nifty 500market median 0.0% · five sessions −3.6% (−3.1 pts vs Nifty 500) · volume 1.7× usual · delivery −17.9 pts against usual · The announcement
- 26 Aug 2024Credit ratingdown 0.20%−0.8 pts vs Nifty 500market median 0.0% · five sessions +4.1% (+2.7 pts vs Nifty 500) · volume 0.4× usual · delivery −5.6 pts against usual · The announcement
- 13 Aug 2024Board or managers changedup 0.78%+1.7 pts vs Nifty 500market median 0.0% · five sessions +0.8% (−0.8 pts vs Nifty 500) · volume 1.0× usual · delivery 0.0 pts against usual · The announcement
- 24 Jul 2024Resultsup 0.23%0.0 pts vs Nifty 500market median −0.7% · five sessions −0.9% (−3.4 pts vs Nifty 500) · volume 4.1× usual · delivery −18.0 pts against usual · The announcement
- 24 Jul 2024Board or managers changedup 0.23%0.0 pts vs Nifty 500market median 0.0% · five sessions −0.9% (−3.4 pts vs Nifty 500) · volume 4.1× usual · delivery −18.0 pts against usual · The announcement
- 27 May 2024Dividendup 1.63%+1.6 pts vs Nifty 500market median 0.0% · five sessions +3.2% (+5.0 pts vs Nifty 500) · volume 5.6× usual · delivery −30.4 pts against usual · The announcement
- 27 May 2024Resultsup 1.63%+1.6 pts vs Nifty 500market median −0.7% · five sessions +3.2% (+5.0 pts vs Nifty 500) · volume 5.6× usual · delivery −30.4 pts against usual · The announcement
- 27 May 2024Board or managers changedup 1.63%+1.6 pts vs Nifty 500market median 0.0% · five sessions +3.2% (+5.0 pts vs Nifty 500) · volume 5.6× usual · delivery −30.4 pts against usual · The announcement
- 1 Mar 2024Board or managers changedup 0.10%−1.2 pts vs Nifty 500market median 0.0% · five sessions +0.9% (−0.5 pts vs Nifty 500) · volume 2.0× usual · delivery −12.8 pts against usual · The announcement
- 2 Feb 2024Dividendup 0.52%−0.2 pts vs Nifty 500market median 0.0% · five sessions +5.3% (+4.2 pts vs Nifty 500) · volume 1.9× usual · delivery −29.1 pts against usual · The announcement
- 2 Feb 2024Resultsup 0.52%−0.2 pts vs Nifty 500market median −0.7% · five sessions +5.3% (+4.2 pts vs Nifty 500) · volume 1.9× usual · delivery −29.1 pts against usual · The announcement
Torrent Pharmaceuticals results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Dealing with a related party in the period | Quarter to Mar 2025 | Standalone | 1,276.57 | 1,277.45 | +0.1% | 12 Jun 2025 | 12 Jun 2025 |
| Dealing with a related party in the period | Quarter to Mar 2025 | Standalone | 1,277.45 | 1,276.57 | −0.1% | 21 May 2025 | 12 Jun 2025 |